ValiRx PLC VAL

ImmuPharma PLC (AIM:IMM, FRA:25I) has signed up Kymos Group as its bioanalytical partner for diabetes drug Kapiglucagon. That completes the outsourced team needed to file for human trials in the US. ValiRx PLC (AIM:VAL, FRA:EAJF) is set to get a second European patent for its cancer-killing peptide from subsidiary Cytolytix. It's targeting triple negative breast cancer and is in talks with a major pharma company. Tertiary Minerals PLC (AIM:TYM, OTC:TTIRF, FRA:TMU) has drilled some strong copper and silver hits at its Mushima North project in Zambia. Lab results are due in the coming weeks, wit

ValiRX CEO Dr Mark Eccleston joined Steve Darling from Proactive to discuss the company’s progress across its expanding oncology and animal health pipeline as the company advances multiple therapeutic assets through its special purpose vehicle (SPV) strategy. Eccleston said the AIM-listed biotechnology company continued to focus on identifying, evaluating and de-risking promising therapeutic assets before advancing them within dedicated commercial entities. Eccleston said the structure allowed each programme to operate with a specialised management focus while leveraging shared expertise acros

ValiRx, the AIM-listed life sciences company focused on early-stage cancer therapeutics and women's health, has raised up to £1.155 million through a placing, subscription, and planned retail offer at 0.2p per share. The shares fell 17% to 0.2p, matching the issue price, which itself...